I noted that fans on Twitter have come to assume Chris Davis is using steroids every time he hits a homer but now we have a well-known sportswriter — Rick Telander of the Chicago Sun-Times — doing it too. Oh, he couches it in the “hey, maybe he’s clean, we just don’t know!” language all of these guys have come to use, but make no mistake: Rick Telander is accusing Chris Davis of using steroids:
People might wonder what the fallout from the baseball’s Steroid Era is.
Try this: Amazing Orioles slugger Chris Davis (in town to play the White Sox) is on pace to hit 61 home runs — Roger Maris’ golden number — and what he gets as a reception instead of cheery anticipation is a lot of raised eyebrows. The first thing that goes through any informed fan’s mind when he or she sees a 6-3, 230-pound muscleman come from almost nowhere and suddenly start ringing the home-run bell is steroids.
He throws in some casual speculation of Miguel Cabrera too. Then he notes that Davis has had a three-month span of homers which is similar to one Rafael Palmeiro once had and stings it with “Palmeiro? Yep, a previously disgraced ’roider.”
Once again it’s worth reminding ourselves that when a blogger said stuff nowhere near as pointed as this a few years ago he was excoriated by the national professional sporting press. Now guys like Telander do it every time a slugger who was not previously thought of as A-list hits some homers and no one cares. Jose Bautista got this treatment a couple of years ago. Davis is getting it now. And these hacks continue to sit there and act like they have earned the right to be gatekeepers of the sport we love. Like they’re some esteemed authority whose judgment should be presumed to be sound.
Baloney. You don’t have to assume Chris Davis is taking some banned substance. You can watch him play well and enjoy it. You really can. If something comes up later, welp, it comes up later and we can reassess what we think about Chris Davis’ accomplishments. But to simply assume like Telander does that everyone who plays this game well must be a cheater is misery personified.
(link via BleedCubbieBlue)
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.